The results demonstrated that while treatment with either low-dose ZK53 or IKE alone did not significantly inhibit tumor growth, ZK53 markedly enhanced tumor sensitivity to SLC7A11 inhibition (Figure 7B). This evidence concerns the gene SLC7A11 and neoplasm.